Dr. Loibl Discusses GeparSepto Trial in Breast Cancer

Professor Sibylle Loibl - 2023 Breast Cancer Trials Annual Scientific MeetingПодробнее

Sibylle Loibl, German Breast Group, Neu-Isenburg, GermanyПодробнее

New drugs in neoadjuvant breast cancer therapyПодробнее

Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast CancerПодробнее

Dr. Brufsky on the COLET Trial for Triple-Negative Breast CancerПодробнее

EBCC6: Chemotherapy for pregnant breast cancer patientsПодробнее

Sibylle Loibl presents the Penelope-B Trial at SanAntonio 2020Подробнее

An Overview of the GeparSepto Trial in Luminal, Triple-Negative, and HER2+ Breast CancerПодробнее

Dr. Boughey Discusses the Z11 Trial in Breast CancerПодробнее

Dr. Michele Blackwood Discusses Advances in Cancer CareПодробнее

Dr. Favret on Extending Survival and Improving Outcomes in Breast CancerПодробнее

Dr. Loi on Immune Cells in HER2+ Breast CancerПодробнее

Dr. Gralow Discusses Toxicities Experienced in the SWOG S0307 TrialПодробнее

Dr. Boughey Discusses the Z11 Trial in Breast CancerПодробнее

Dr. Steven Shak on the Results of the TAILORx Trial for Breast CancerПодробнее

Phase III KATHERINE Clinical Trial: Kommentar Prof. Dr. med. Sibylle Loibl, FrankfurtПодробнее

Why Clinical Trial Participation is Important to Advance Breast Cancer TreatmentПодробнее

Dr. Smith Discusses the Brachytherapy Breast Cancer TrialПодробнее

Kalinsky discusses results from RxPONDER breast cancer clinical trialПодробнее